TENAX THERAPEUTICS, INC.
Business
Tenax Therapeutics is a development-stage pharmaceutical company pursuing clinical trials of levosimendan and imatinib for cardiopulmonary diseases, including pulmonary hypertension in heart failure with preserved ejection fraction and pulmonary arterial hypertension. The company conducts Phase 3 trials of oral levosimendan in PH-HFpEF patients and operates in the U.S. and Canada under an exclusive license from Orion Corporation for levosimendan, with plans for global expansion.
Summary from 10-K filed 2026-03-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 33 | 13 | 3 | 5 | 25 | |
| General and administrative | 24 | 7 | 5 | 6 | 8 | |
| Total operating expenses | 56 | 19 | 8 | 11 | 33 | |
| Net operating loss | −56 | −19 | 8 | 11 | 33 | |
| Interest income | 4 | 2 | −484,000 | — | — | |
| Interest expense | 0 | −23,000 | 24,000 | 4,443 | 949 | |
| Other (expense) income, net | −33,000 | 1,000 | −63,000 | −9,191 | — | |
| Net loss | −53 | −18 | 8 | 11 | 32 | |
| Net loss per share, basic | −1.34 | −1.15 | −31.04 | — | — | |
| Net loss per share, diluted | −1.34 | −1.15 | −31.04 | — | — | |
| Weighted average number of common shares and prefunded warrants outstanding, basic | 39 | 15 | 248,447 | — | — | |
| Weighted average number of common shares and prefunded warrants outstanding, diluted | 39 | 15 | 248,447 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 98 | 95 | 10 | 2 | 6 | |
| Prepaid expenses | 6 | 2 | 2 | 738,927 | 105,078 | |
| Other current assets | 1 | 64,000 | 252,000 | 345,856 | 0 | |
| Total current assets | 104 | 97 | 12 | 3 | 6 | |
| Total assets | 104 | 97 | 12 | 3 | 6 | |
| Accounts payable | 6 | 3 | 2 | 448,425 | 859,638 | |
| Accrued liabilities | 1 | 2 | 1 | 775,045 | 704,340 | |
| Total current liabilities | 7 | 5 | 4 | 2 | 2 | |
| Total liabilities | 7 | 5 | 4 | 2 | 2 | |
| Commitments and contingencies; see Note 5 | — | — | — | — | — | |
| Preferred stock, undesignated, authorized 4,818,654 shares Series A Preferred stock, par value $0.0001, issued 5,181,346 shares; outstanding 210, as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value $0.0001 per share; authorized 400,000,000 shares; issued and outstanding 9,314,130 as of December 31, 2025 and 3,420,906 as of December 31, 2024, respectively | 1,000 | 0 | 0 | 3 | 2,521 | |
| Additional paid-in capital | 465 | 407 | 305 | 291 | 283 | |
| Accumulated deficit | −367 | −315 | −297 | −290 | −278 | |
| Total stockholders' equity | 97 | 92 | 8 | 1 | 4 | |
| Total liabilities and stockholders' equity | 104 | 97 | 12 | 3 | 6 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Loss | −53 | −18 | −8 | −11 | −32 | |
| Interest on debt instrument | 0 | 23,000 | 24,000 | 4,443 | 949 | |
| Stock-based compensation | 19 | 1 | 191,000 | — | — | |
| Prepaid expenses and other current assets | −5 | 58,000 | — | −980,822 | −22,500 | |
| Accounts payable | 3 | 1 | 2 | — | — | |
| Accrued liabilities | −421,000 | 523,000 | 237,000 | — | — | |
| Net cash used in operating activities | −36 | −15 | −6 | −11 | −11 | |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of issuance costs | 23 | 100 | 14 | 8 | — | |
| Proceeds from the exercise of warrants | 15 | 68,000 | 1,000 | 2,063 | 544,651 | |
| Payments on short-term note | 0 | −501,000 | −624,000 | 0 | — | |
| Net cash provided by financing activities | 39 | 100 | 14 | 8 | 10 | |
| Net change in cash and cash equivalents | 3 | 85 | 8 | −3 | −666,319 | |
| Cash paid for interest | 0 | 23,000 | 24,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TENAX THERAPEUTICS, INC.'s CIK number?
TENAX THERAPEUTICS, INC.'s SEC CIK number is 0000034956 (34956). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TENAX THERAPEUTICS, INC.'s SEC filings?
All of TENAX THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did TENAX THERAPEUTICS, INC. last report earnings?
TENAX THERAPEUTICS, INC. (TENX) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218224). This is TENAX THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is TENAX THERAPEUTICS, INC.'s most recent earnings 8-K?
TENAX THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218224. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View TENAX THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →